These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 15587144)

  • 41. The impact of LH serum concentration on the clinical outcome of IVF cycles in patients receiving two regimens of clomiphene citrate/gonadotrophin/0.25 mg cetrorelix.
    Tavaniotou A; Albano C; Van Steirteghem A; Devroey P
    Reprod Biomed Online; 2003 Jun; 6(4):421-6. PubMed ID: 12831586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R
    J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
    Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
    Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
    Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Depot versus daily administration of gonadotrophin releasing hormone agonist protocols for pituitary desensitization in assisted reproduction cycles.
    Albuquerque LE; Saconato H; Maciel MC
    Cochrane Database Syst Rev; 2002; (3):CD002808. PubMed ID: 12137658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, cetrorelix, and GnRH agonists.
    Nikolettos N; Al-Hasani S; Felberbaum R; Demirel LC; Riethmüller-Winzen H; Reissmann T; Schöpper B; Sturm R; Diedrich K
    Eur J Obstet Gynecol Reprod Biol; 2000 Nov; 93(1):91-5. PubMed ID: 11000511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and Safety of In Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Among Patients with Endometriosis After a Shortened Protocol of Long-Term Pituitary Downregulation.
    Kong H; Bu Z; Guo Y; Wang F; Shi H; Hu L; Sun Y
    Med Sci Monit; 2019 Jun; 25():4377-4383. PubMed ID: 31187785
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pregnancy rates in an IVF program. Use of the flare-up protocol after failure with long regimens of GnRH-a.
    Karacan M; Erkan H; Karabulut O; Sarikamiş B; Camlibel T; Benhabib M
    J Reprod Med; 2001 May; 46(5):485-9. PubMed ID: 11396377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin-releasing hormone agonist short regimen on alternate days and an antagonist protocol for assisted fertilization treatments.
    Maldonado LG; Franco JG; Setti AS; Iaconelli A; Borges E
    Fertil Steril; 2013 May; 99(6):1615-22. PubMed ID: 23394779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes.
    Hill MJ; Chason RJ; Payson MD; Segars JH; Csokmay JM
    Reprod Biomed Online; 2012 Sep; 25(3):284-91. PubMed ID: 22796230
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Top quality blastocyst formation rates in relation to progesterone levels on the day of oocyte maturation in GnRH antagonist IVF/ICSI cycles.
    Vanni VS; Somigliana E; Reschini M; Pagliardini L; Marotta E; Faulisi S; Paffoni A; Vigano' P; Vegetti W; Candiani M; Papaleo E
    PLoS One; 2017; 12(5):e0176482. PubMed ID: 28520729
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?
    Kedem A; Tsur A; Haas J; Yerushalmi GM; Hourvitz A; Machtinger R; Orvieto R
    Fertil Steril; 2014 Jun; 101(6):1624-8. PubMed ID: 24680364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of length of controlled ovarian hyperstimulation using a gonadotropin-releasing hormone antagonist on in vitro fertilization pregnancy rates.
    Royster GD; Retzloff MG; Robinson RD; King JA; Propst AM
    J Reprod Med; 2012; 57(9-10):415-20. PubMed ID: 23091989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The risk of ectopic pregnancy following GnRH agonist triggering compared with hCG triggering in GnRH antagonist IVF cycles.
    Sahin S; Ozay A; Ergin E; Turkgeldi L; Kürüm E; Ozornek H
    Arch Gynecol Obstet; 2015 Jan; 291(1):185-91. PubMed ID: 25078054
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
    Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
    Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist.
    Kummer N; Benadiva C; Feinn R; Mann J; Nulsen J; Engmann L
    Fertil Steril; 2011 Jul; 96(1):63-8. PubMed ID: 21565337
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effects of uterine adenomyosis on clinical outcomes of infertility patients treated with in vitro fertilization/intracytoplasmic sperm injection-embryo transfer (IVF/ICSI-ET)].
    Tao T; Chen S; Chen X; Ye D; Xu L; Tian X; Liu Y; Niu J
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Feb; 35(2):248-51. PubMed ID: 25736122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early pregnancy loss is significantly higher after day 3 single embryo transfer than after day 5 single blastocyst transfer in GnRH antagonist stimulated IVF cycles.
    Papanikolaou EG; Camus M; Fatemi HM; Tournaye H; Verheyen G; Van Steirteghem A; Devroey P
    Reprod Biomed Online; 2006 Jan; 12(1):60-5. PubMed ID: 16454935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.